title: Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
authors.affiliation: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. Electronic address: leochen@nhri.org.tw.
authors.forename: Li-Tzong
authors.initials: LT
authors.lastname: Chen
authors.affiliation: Washington University School of Medicine, St Louis, MO, USA.
authors.forename: Andrea
authors.initials: A
authors.lastname: Wang-Gillam
authors.affiliation: TGen, Phoenix, AZ, USA; HonorHealth, Scottsdale, AZ, USA.
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Von Hoff
authors.affiliation: Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
authors.forename: Eliel
authors.initials: E
authors.lastname: Bayever
authors.affiliation: Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Belanger
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*